Telephone Often Delivers News of Breast Cancer Diagnosis

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 5
Volume 15
Issue 5

A survey of 121 breast cancer patients attending a breast cancer clinic found that 59% had received their "bad news" diagnosis over the telephone (mainly in their local area). Brianna J. Crawford, research coordinator at the Breast Diagnostic and Cancer Clinic, Mayo Clinic, Rochester, Minnesota, reported the study results in a poster session at the American Psychosocial Oncology Society (APOS) Third Annual Conference (P14-3).

AMELIA ISLAND, Florida—A survey of 121 breast cancer patients attending a breast cancer clinic found that 59% had received their "bad news" diagnosis over the telephone (mainly in their local area). Brianna J. Crawford, research coordinator at the Breast Diagnostic and Cancer Clinic, Mayo Clinic, Rochester, Minnesota, reported the study results in a poster session at the American Psychosocial Oncology Society (APOS) Third Annual Conference (P14-3).

The "good news," she said, is that the women were not overly distressed to receive their diagnosis this way. "All the guidelines say not to do it over the phone, but in our study, patient satisfaction did not really differ at all between people who received their diagnosis over the phone vs people who received it in a face-to-face encounter," she said.

The women were asked about their experience of receiving their diagnosis in a 35-item questionnaire from 1 to 54 days after learning they had breast cancer. The majority said they got the news from general physicians, followed by surgeons, radiologists, nurses, physician's assistants, gynecologists, breast specialists, other specialists, family members, and, lastly, secretaries. Patients described their relationship with the person who gave them their diagnosis as excellent (21%), good (25%), satisfactory (26%), inadequate (7%), and poor (5%). Nearly 15% said they did not know the person well enough to rate or describe the relationship.

The mean length of time spent on the telephone to disclose the diagnosis was 7.9 minutes, compared to 26.3 minutes for the face-to-face disclosure. Patient satisfaction was the same for both groups of women. "This is important to know, because all of the literature and patient-communication research out there right now is saying that we need to tell people face to face and stay close to them. But, in fact, what we are finding is that the news is being delivered by telephone all over the United States. Since that is the reality, we need to find out how to share the cancer diagnosis in the best way for the patient," Ms. Crawford said. While it should be noted that these findings highlight important new considerations for "breaking bad news" to patients, she said, the issue should be further explored via larger and population-based studies.

Patients frequently have to travel long distances to get a face-to-face diagnosis, so getting the news by phone may actually be better for them, she added. "For some women, it may be a good thing to be able to offer them the option of receiving that news at home, in a comfortable place, surrounded by friends or family. It might be more logical for them to receive it there," she said.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.